Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPB-01 for Bullous Pemphigoid
NCT01408550Phase 3Completed
- Sponsor
- Nihon Pharmaceutical
- Start
- Aug 2011
- Primary completion
- Sep 2013
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, PEGylated Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing NPB-01 with Placebo (2 arms). Primary endpoint: Pemphigus Disease Area Index at 15 days. Started Aug 2011; status: completed.
02
Drugs
NPB-01-ME
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT01408550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01408550.